Master Alliance Provisions Guide (MAPGuide)

MPP – Biovac, mRNA Vaccine Technology Transfer Agreement

  • Equitable access | Affordable pricing
  • Equitable access | Preparedness & response

4. OBLIGATIONS OF BIOVAC

Biovac undertakes to:

[….]

4.6 In the event that Biovac develops and commercialises a Product that is responsive to a Public Health Emergency of International Concern as declared by WHO, to as soon as practically possible make available no less than ten percent of its real-time production capacity of Product for WHO and/or Public Sector Agencies at a price to be negotiated in good faith, but in no event to exceed its Cost of Production plus a twenty percent mark-up.